Nolus (Montelukast)

Montelukast, the active ingredient in Nolus, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children as prescribed by a healthcare professional. The medication works by blocking specific inflammatory mediators that cause narrowing of the airways.

GNH USA supplies Nolus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage conditions mediated by leukotrienes, primarily within the respiratory and allergic disease spectrum. - Asthma: reduces bronchoconstriction and airway inflammation, helping to prevent asthma attacks. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic inflammation.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramps. - Cough: transient irritation of the throat. - Upper respiratory infection: mild cold‑like symptoms. - Diarrhea: loose stools that resolve spontaneously. - Fatigue: feeling of tiredness without exertion.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, or hives requiring medical attention. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatotoxicity: abnormal liver enzymes indicating liver stress. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Anaphylaxis: rapid onset of breathing difficulty and hypotension. - Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Assess liver function: consider baseline tests in patients with hepatic impairment. - Review concomitant medications: avoid drugs that strongly induce CYP3A4 enzymes. - Use caution in children: pediatric dosing should follow prescriber guidance. - Pregnancy and lactation: discuss potential risks with the patient as data are limited. - Store below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that may lower montelukast plasma levels. - Phenobarbital: reduces drug exposure through hepatic enzyme induction.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect; monitor INR. - Carbamazepine: can modestly decrease montelukast concentrations. - Fluconazole: potential slight increase in exposure; observe for side effects. - St. John's Wort: herbal inducer that may reduce effectiveness.